Miejsce ranolazyny w nowoczesnej farmakoterapii przewlekłego zespołu wieńcowego. Doświadczenia własne Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
cze 30, 2025
Słowa kluczowe:
adherencja, cukrzyca typu 2, przewlekły zespół wieńcowy, ranolazyna, zaburzenia rytmu
##plugins.themes.bootstrap3.article.main##
Abstrakt
Ranolazyna to przeciwdławicowy lek o wielokierunkowym mechanizmie działania, uzupełniającym efekty klasycznej farmakoterapii przewlekłego zespołu wieńcowego. Unikatow główny mechanizm jej działania wynika z hamowania późnego prądu sodowego w błonie komórkowej kardiomiocytu. W efekcie dochodzi do poprawy relaksacji i podatności miokardium, co redukuje częstość zaburzeń rytmu obserwowanych. Swoisty antyarytmiczny mechanizm działania ranolazyny wydłuża czas potencjału czynnościowego i zmniejsza pobudliwość elektryczną komórek mięśnia sercowego. Ranolazyna ma również dodatkowe działanie kardioprotekcyjne w warunkach niedokrwienia. Blokuje ona β-oksydację kwasów tłuszczowych, czego efektem jest przewaga spalania glukozy. Lek jest bardzo dobrze tolerowany przez chorych, a jego skuteczność sprawiła, że w 2018 r. został on uwzględniony w klasyfikacji leków stosowanych w nadkomorowych i komorowych zaburzeń rytmu serca.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Grabysa, R., & Ciołek, A. (2025). Miejsce ranolazyny w nowoczesnej farmakoterapii przewlekłego zespołu wieńcowego. Doświadczenia własne . Medycyna Faktów , 18(2(67), 296-303. https://doi.org/10.24292/01.MF.0225.19
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Roth GA, Abate D, Abate KH et al. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet. 2018; 392(10159): 1736-88. http://doi.org/10.1016/S0140-6736(18)32203-7.
2. NFZ o Zdrowiu. Choroba Niedokrwienna Serca. 2020 .
3. Vrints C, Andreotti F, Koskinas KC et al. 2024 ESC Guidelines for the management of chronic coronary syndromes: Developed by the task force for the management of chronic coronary syndromes of the European Society of Cardiology (ESC) Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2024; 45(36): 3415-37. http://doi.org/10.1093/eurheartj/ehae177.
4. Eisen A, Bhatt DL, Steg PG et al. Angina and Future Cardiovascular Events in Stable Patients With Coronary Artery Disease: Insights From the Reduction of Atherothrombosis for Continued Health (REACH) Registry. J Am Heart Assoc. 2016; 5(10): e004080. http://doi.org/10.1161/JAHA.116.004080.
5. Virani SS, Newby LK, Arnold SV et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2023; 148(9): e9-e119. http://doi.org/10.1161/CIR.0000000000001168.
6. Antzelevitch C, Belardinelli L, Zygmunt AC et al. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation. 2004; 110(8): 904-10. http://doi.org/10.1161/01.CIR.0000139333.83620.5D.
7. Fraser H, Belardinelli L, Wang L et al. Ranolazine decreases diastolic calcium accumulation caused by ATX-II or ischemia in rat hearts. J Mol Cell Cardiol. 2006; 41(6): 1031-8. http://doi.org/10.1016/j.yjmcc.2006.08.012.
8. Kusz B, Mizia-Stec K. Ranolazine – a new antiarrhythmic agent? WDR. 2015; 2(35): 4-9. http://doi.org/10.5604/18967892.1154001.
9. Lei M, Wu L, Terrar DA et al. Modernized Classification of Cardiac Antiarrhythmic Drugs. Circulation. 2018; 138(17): 1879-96. http://doi.org/10.1161/CIRCULATIONAHA.118.035455.
10. Belardinelli L, Shryock JC, Fraser H. Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazine. Heart Br Card Soc. 2006; 92 Suppl 4(Suppl 4): iv6-iv14. http://doi.org/10.1136/hrt.2005.078790.
11. Chaitman BR, Skettino SL, Parker JO et al. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol. 2004; 43(8): 1375-82. http://doi.org/10.1016/j.jacc.2003.11.045.
12. Sendon JL, Lee S, Cheng ML et al. Effects of ranolazine on exercise tolerance and angina frequency in patients with severe chronic angina receiving maximally-tolerated background therapy: analysis from the Combination Assessment of Ranolazine In Stable Angina (CARISA) randomized trial. Eur J Prev Cardiol. 2012; 19(5): 952-9. http://doi.org/10.1177/2047487312450133.
13. Scirica BM, Morrow DA, Hod H et al. Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation. 2007; 116(15): 1647-52. http://doi.org/10.1161/CIRCULATIONAHA.107.724880.
14. De Ferrari GM, Maier LS, Mont L et al. Ranolazine in the treatment of atrial fibrillation: Results of the dose-ranging RAFFAELLO (Ranolazine in Atrial Fibrillation Following An ELectricaL CardiOversion) study. Heart Rhythm. 2015; 12(5): 872-8. http://doi.org/10.1016/j.hrthm.2015.01.021.
15. Koskinas KC, Fragakis N, Katritsis D et al. Ranolazine enhances the efficacy of amiodarone for conversion of recent-onset atrial fibrillation. Europace. 2014; 16(7): 973-9. http://doi.org/10.1093/europace/eut407.
16. Timmis AD, Chaitman BR, Crager M. Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes. Eur Heart J. 2006; 27(1): 42-8. http://doi.org/10.1093/eurheartj/ehi495.
17. Morrow DA, Scirica BM, Chaitman BR et al. Evaluation of the glycometabolic effects of ranolazine in patients with and without diabetes mellitus in the MERLIN-TIMI 36 randomized controlled trial. Circulation. 2009; 119(15): 2032-9. http://doi.org/10.1161/CIRCULATIONAHA.107.763912.
18. Teoh IH, Banerjee M. Effect of ranolazine on glycaemia in adults with and without diabetes: a meta-analysis of randomised controlled trials. Open Heart. 2018; 5(2): e000706. http://doi.org/10.1136/openhrt-2017-000706.
19. Dhalla AK, Yang M, Ning Y et al. Blockade of Na+ channels in pancreatic α-cells has antidiabetic effects. Diabetes. 2014; 63(10): 3545-56. http://doi.org/10.2337/db13-1562.
20. Morrow DA, Scirica BM, Sabatine MS et al. B-type natriuretic peptide and the effect of ranolazine in patients with non-ST-segment elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary-Thrombolysis In Myocardial Infarction 36) trial. J Am Coll Cardiol. 2010; 55(12): 1189-96. http://doi.org/10.1016/j.jacc.2009.09.068.
21. Cempaka Putri DKS, Andrianto A, Al-Farabi MJ et al. Efficacy of Ranolazine to Improve Diastolic Performance in Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-analysis. Eur Cardiol. 2023; 18: e02. http://doi.org/10.15420/ecr.2022.10.
22. McDonagh TA, Metra M, Adamo M et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2022; 24(1): 4-131. http://doi.org/10.1002/ejhf.2333.
23. Kofler T, Hess S, Moccetti F et al. Efficacy of Ranolazine for Treatment of Coronary Microvascular Dysfunction – A Systematic Review and Meta-analysis of Randomized Trials. CJC Open. 2021; 3(1): 101-8. http://doi.org/10.1016/j.cjco.2020.09.005.
24. Ahmed B, Mondragon J, Sheldon M et al. Impact of ranolazine on coronary microvascular dysfunction (MICRO) study. Cardiovasc Revasc Med. 2017; 18(6): 431-5. http://doi.org/10.1016/j.carrev.2017.04.012.
25. Ling H, Fu S, Xu M et al. Ranolazine for improving coronary microvascular function in patients with nonobstructive coronary artery disease: a systematic review and meta-analysis with a trial sequential analysis of randomized controlled trials. Quant Imaging Med Surg. 2024; 14(2): 1451-65. http://doi.org/10.21037/qims-23-1029.
26. Ferrari R, Ford I, Fox K et al. Efficacy and safety of trimetazidine after percutaneous coronary intervention (ATPCI): a randomised, double-blind, placebo-controlled trial. The Lancet. 2020; 396(10254): 830-8. http://doi.org/10.1016/S0140-6736(20)31790-6.
27. Koren MJ, Crager MR, Sweeney M. Long-term safety of a novel antianginal agent in patients with severe chronic stable angina: the Ranolazine Open Label Experience (ROLE). J Am Coll Cardiol. 2007; 49(10): 1027-34. http://doi.org/10.1016/j.jacc.2006.10.067.
2. NFZ o Zdrowiu. Choroba Niedokrwienna Serca. 2020 .
3. Vrints C, Andreotti F, Koskinas KC et al. 2024 ESC Guidelines for the management of chronic coronary syndromes: Developed by the task force for the management of chronic coronary syndromes of the European Society of Cardiology (ESC) Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2024; 45(36): 3415-37. http://doi.org/10.1093/eurheartj/ehae177.
4. Eisen A, Bhatt DL, Steg PG et al. Angina and Future Cardiovascular Events in Stable Patients With Coronary Artery Disease: Insights From the Reduction of Atherothrombosis for Continued Health (REACH) Registry. J Am Heart Assoc. 2016; 5(10): e004080. http://doi.org/10.1161/JAHA.116.004080.
5. Virani SS, Newby LK, Arnold SV et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2023; 148(9): e9-e119. http://doi.org/10.1161/CIR.0000000000001168.
6. Antzelevitch C, Belardinelli L, Zygmunt AC et al. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation. 2004; 110(8): 904-10. http://doi.org/10.1161/01.CIR.0000139333.83620.5D.
7. Fraser H, Belardinelli L, Wang L et al. Ranolazine decreases diastolic calcium accumulation caused by ATX-II or ischemia in rat hearts. J Mol Cell Cardiol. 2006; 41(6): 1031-8. http://doi.org/10.1016/j.yjmcc.2006.08.012.
8. Kusz B, Mizia-Stec K. Ranolazine – a new antiarrhythmic agent? WDR. 2015; 2(35): 4-9. http://doi.org/10.5604/18967892.1154001.
9. Lei M, Wu L, Terrar DA et al. Modernized Classification of Cardiac Antiarrhythmic Drugs. Circulation. 2018; 138(17): 1879-96. http://doi.org/10.1161/CIRCULATIONAHA.118.035455.
10. Belardinelli L, Shryock JC, Fraser H. Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazine. Heart Br Card Soc. 2006; 92 Suppl 4(Suppl 4): iv6-iv14. http://doi.org/10.1136/hrt.2005.078790.
11. Chaitman BR, Skettino SL, Parker JO et al. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol. 2004; 43(8): 1375-82. http://doi.org/10.1016/j.jacc.2003.11.045.
12. Sendon JL, Lee S, Cheng ML et al. Effects of ranolazine on exercise tolerance and angina frequency in patients with severe chronic angina receiving maximally-tolerated background therapy: analysis from the Combination Assessment of Ranolazine In Stable Angina (CARISA) randomized trial. Eur J Prev Cardiol. 2012; 19(5): 952-9. http://doi.org/10.1177/2047487312450133.
13. Scirica BM, Morrow DA, Hod H et al. Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation. 2007; 116(15): 1647-52. http://doi.org/10.1161/CIRCULATIONAHA.107.724880.
14. De Ferrari GM, Maier LS, Mont L et al. Ranolazine in the treatment of atrial fibrillation: Results of the dose-ranging RAFFAELLO (Ranolazine in Atrial Fibrillation Following An ELectricaL CardiOversion) study. Heart Rhythm. 2015; 12(5): 872-8. http://doi.org/10.1016/j.hrthm.2015.01.021.
15. Koskinas KC, Fragakis N, Katritsis D et al. Ranolazine enhances the efficacy of amiodarone for conversion of recent-onset atrial fibrillation. Europace. 2014; 16(7): 973-9. http://doi.org/10.1093/europace/eut407.
16. Timmis AD, Chaitman BR, Crager M. Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes. Eur Heart J. 2006; 27(1): 42-8. http://doi.org/10.1093/eurheartj/ehi495.
17. Morrow DA, Scirica BM, Chaitman BR et al. Evaluation of the glycometabolic effects of ranolazine in patients with and without diabetes mellitus in the MERLIN-TIMI 36 randomized controlled trial. Circulation. 2009; 119(15): 2032-9. http://doi.org/10.1161/CIRCULATIONAHA.107.763912.
18. Teoh IH, Banerjee M. Effect of ranolazine on glycaemia in adults with and without diabetes: a meta-analysis of randomised controlled trials. Open Heart. 2018; 5(2): e000706. http://doi.org/10.1136/openhrt-2017-000706.
19. Dhalla AK, Yang M, Ning Y et al. Blockade of Na+ channels in pancreatic α-cells has antidiabetic effects. Diabetes. 2014; 63(10): 3545-56. http://doi.org/10.2337/db13-1562.
20. Morrow DA, Scirica BM, Sabatine MS et al. B-type natriuretic peptide and the effect of ranolazine in patients with non-ST-segment elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary-Thrombolysis In Myocardial Infarction 36) trial. J Am Coll Cardiol. 2010; 55(12): 1189-96. http://doi.org/10.1016/j.jacc.2009.09.068.
21. Cempaka Putri DKS, Andrianto A, Al-Farabi MJ et al. Efficacy of Ranolazine to Improve Diastolic Performance in Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-analysis. Eur Cardiol. 2023; 18: e02. http://doi.org/10.15420/ecr.2022.10.
22. McDonagh TA, Metra M, Adamo M et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2022; 24(1): 4-131. http://doi.org/10.1002/ejhf.2333.
23. Kofler T, Hess S, Moccetti F et al. Efficacy of Ranolazine for Treatment of Coronary Microvascular Dysfunction – A Systematic Review and Meta-analysis of Randomized Trials. CJC Open. 2021; 3(1): 101-8. http://doi.org/10.1016/j.cjco.2020.09.005.
24. Ahmed B, Mondragon J, Sheldon M et al. Impact of ranolazine on coronary microvascular dysfunction (MICRO) study. Cardiovasc Revasc Med. 2017; 18(6): 431-5. http://doi.org/10.1016/j.carrev.2017.04.012.
25. Ling H, Fu S, Xu M et al. Ranolazine for improving coronary microvascular function in patients with nonobstructive coronary artery disease: a systematic review and meta-analysis with a trial sequential analysis of randomized controlled trials. Quant Imaging Med Surg. 2024; 14(2): 1451-65. http://doi.org/10.21037/qims-23-1029.
26. Ferrari R, Ford I, Fox K et al. Efficacy and safety of trimetazidine after percutaneous coronary intervention (ATPCI): a randomised, double-blind, placebo-controlled trial. The Lancet. 2020; 396(10254): 830-8. http://doi.org/10.1016/S0140-6736(20)31790-6.
27. Koren MJ, Crager MR, Sweeney M. Long-term safety of a novel antianginal agent in patients with severe chronic stable angina: the Ranolazine Open Label Experience (ROLE). J Am Coll Cardiol. 2007; 49(10): 1027-34. http://doi.org/10.1016/j.jacc.2006.10.067.